

www.SpectraIntelligence.com  
Tel: +44 (0) 20 8671 7726  
Fax: +44 (0) 20 8678 7731  
enquiries@spectrainelligence.com

www.ArrowheadPublishers.com  
Tel: +1 866 397 1376 or 1 312 244 3703  
Fax: +1 866 397 1376 or 1 312 244 3703  
sales@arrowheadpublishers.net

## **Indian Generics, 2008-2012: A Growing Threat to Westernised Markets**

**Publication Date: January 2008**

**Code: SP0081**

©2008 Spectra Intelligence and Arrowhead Publishers

All rights reserved. No part of this publication may be reproduced, stored, printed, transmitted, broadcast, retrieved or utilized in any form or by any electronic, mechanical, photocopying, recording or other means known now or hereafter invented without permission from the Publisher. This publication may not be resold, lent, hired out or otherwise disposed of by way of trade in any form of binding or cover other than that in which it is published, without the prior consent of the Publisher. While every effort has been made to ensure the data presented is accurate, Spectra Intelligence cannot accept responsibility or liability for errors, omissions, misinterpretations, or completeness. The views and opinions expressed herein are those of the Publisher and may be forward looking; Spectra Intelligence accepts no responsibility for actions or events that may arise as a result of the comment or advice contained in its publications.

### **TABLE OF CONTENTS [ABRIDGED]**

Contents List	4
List of Tables	7
List of Figures	8
Executive Summary	9
<b>1. INTRODUCTION TO THE INDIAN PHARMACEUTICAL INDUSTRY</b>	<b>13</b>
<hr/>	
1.0 A Brief History	14
1.1 The First Companies	14
1.2 Government Measures to Encourage the Industry	15
1.2.1 Patents	16
1.2.2 Price Controls	18
1.2.3 Government Incentives	20
1.3 Leading Companies	21
1.3.1 The Top Ten Indian Pharmaceutical Companies in 2007	23
1.4 Changes in National Pharmaceutical Export-Import Ratios	24
1.4.1 The Shift from Active Pharmaceutical Ingredients to Formulations	25
1.5 The Medium-to-Small Players	26
1.6 Overseas Presence in the Indian Market	27
1.6.1 Multinational Branded Companies	28
1.6.2 Generic Companies	29
<b>2. GROWTH OF THE INDIAN GENERICS INDUSTRY</b>	<b>30</b>
<hr/>	
2.0 History of the Indian Generics Industry	31
2.1 Origins - How did it all Start?	31
2.1.1 The Ladder to Success	31
2.2 Reverse Engineering	32

2.3	Speed to Market	33
2.4	Branded Generics - The Indian Way	34
2.5	Growth Strategies and Drivers	36
2.5.1	Active Pharmaceutical Ingredients	37
2.5.2	Contract Manufacture of Formulations	39
2.5.3	Own Registrations Abroad	40
2.5.4	Patent Challenges	44
2.5.5	Subsidiaries/Joint-Ventures	46
2.5.6	Acquisitions - The Rationale	47
2.5.6.1	Recent Acquisitions	48

### **3. INDIAN DRUG LEGISLATION** **50**

---

3.0	Legislative Background	51
3.1	The Drugs and Cosmetics Act, 1940	51
3.2	Drug Policy of 1986	51
3.3	Liberalisation Since 1991	53
3.4	Pharmaceutical Registration	55
3.5	Data Exclusivity	57
3.6	Barriers to Foreign Ownership	58
3.7	Price Controls	59
3.8	Patents and Intellectual Property	61
3.8.1	Indian Patents Third Amendment Bill, 2005	61
3.8.2	Trade-Related Intellectual Property Rights (TRIPS)	62
3.8.3	Doha Declaration	63
3.8.4	Impact on International Relations	64
3.9	Export Incentives	65

### **4. THE INDIAN DRUG MARKET** **67**

---

4.0	Domestic Market and Healthcare System	68
4.1	Market Size and Drivers of Growth	68
4.1.1	Market Size	68
4.1.2	Growth Drivers	70
4.1.2.1	Increased Prosperity and Life Expectancy	70
4.1.2.2	Improving Transport	71
4.1.2.3	Healthcare Expenditure	72
4.2	Leading Domestic Companies	73
4.3	Leading Foreign Players	75
4.4	The Indian Market in an International Context	77
4.5	Market Growth - Past and Future	78
4.6	The Healthcare System	79
4.6.1	Basic Healthcare	79
4.6.2	Hospitals	80
4.6.3	Health Insurance	80
4.6.3.1	Social Health Insurance	80
4.6.3.2	Private Health Insurance	81
4.6.4	The Poor	81
4.7	Traditional, Herbal and Ayurvedic Medicines	82
4.8	Factors Influencing Pricing	83

### **5. COMPANY PROFILES** **86**

---

<b>5.1</b>	<b>[Company]</b>	<b>87</b>
5.1.1	History	87
5.1.2	Sales Growth	87
5.1.3	Major Products	88
5.1.4	Overseas Presence	88

5.1.4.1	United States	88
5.1.4.2	Europe	89
<b>5.2</b>	<b>[Company]</b>	<b>89</b>
5.2.1	History	89
5.2.2	Sales Growth	89
5.2.3	Major Products	90
5.2.4	Overseas Presence	90
<b>5.3</b>	<b>[Company]</b>	<b>91</b>
5.3.1	History	91
5.3.2	Sales Growth	92
5.3.3	Major Products	93
5.3.4	Overseas Presence	93
<b>5.4</b>	<b>[Company]</b>	<b>93</b>
5.4.1	History	93
5.4.2	Sales Growth	94
5.4.3	Major Products	95
5.4.4	Overseas Presence	96
<b>5.5</b>	<b>[Company]</b>	<b>96</b>
5.5.1	History	96
5.5.2	Sales Growth	97
5.5.3	Major Products	97
5.5.4	Overseas Presence	98
<b>5.6</b>	<b>[Company]</b>	<b>98</b>
5.6.1	History	98
5.6.2	Sales Growth	99
5.6.3	Major Products	100
5.6.4	Overseas Presence	101
<b>5.7</b>	<b>[Company]</b>	<b>101</b>
5.7.1	History	101
5.7.2	Sales Growth	102
5.7.3	Major Products	102
5.7.4	Overseas Presence	103
<b>5.8</b>	<b>[Company]</b>	<b>103</b>
5.8.1	History	103
5.8.2	Sales Growth	104
5.8.3	Major Products	104
5.8.4	Overseas Presence	105
<b>5.9</b>	<b>[Company]</b>	<b>105</b>
5.9.1	History	105
5.9.2	Sales Growth	106
5.9.3	Major Products	107
5.9.4	Overseas Presence	107
<b>5.10</b>	<b>[Company]</b>	<b>108</b>
5.10.1	History	108
5.10.2	Sales Growth	109
5.10.3	Major Products	109
5.10.4	Overseas Presence	110

---

## **6. OUTLOOK FOR THE INDIAN GENERICS INDUSTRY** **111**

6.1	Growth Opportunities and Possible Threats for Indian Companies	112
6.1.1	Opportunities	112
6.1.3	Acquisitions	116
6.2	Threats	117
6.2.1	Market Saturation and Consolidation	117
6.2.2	Competition	119
6.3	Research and Development	120
6.3.1	New Developments	121
6.3.2	Alliances	122

6.4	Opportunities in India for Overseas Companies	123
-----	---	-----

---

<b>7.</b>	<b>CONCLUSIONS AND INSIGHTS FOR THE INDIAN GENERICS MARKET</b>	<b>126</b>
-----------	--	------------

---

7.1	Is India the Pharmaceutical Giant of the Future?	127
7.1.1	Domestic Market	127
7.1.2	International Growth	127
7.1.3	Environmental Concerns	128
7.1.4	Growth through Consolidation	129
7.1.5	Growth through New Products	129
7.1.5.1	Generics	129
7.1.5.2	New Chemical Entities	130
7.2	Are Indian Companies Allies or Opponents?	132
7.2.1	Alliances	132
7.2.2	Indian Companies as Competitors	133
7.3	Who will be Tomorrow's Generic Champions?	134
7.3.1	The Future	137

### **List of Tables**

Table 1	Presence of Asian Pharmaceutical Companies at Annual Global Exhibitions, 1997-2005	11
Table 1.1	Pricing Differentials of Ciprofloxacin (10 x 500mg tablets) in 2006	18
Table 1.2	Price Comparisons of Doxycycline in Europe, the US, and India	20
Table 1.3	Top Ten Indian Pharmaceutical Companies by Turnover, 2005	22
Table 1.4	Annual Revenues of the Leading Indian Drug Manufacturers, 2006-2007	24
Table 1.5	Value Growth Trends of Drug Exports and Imports in India, 1999-2005 (Crore Rupees)	25
Table 1.6	Domestic Sales of Medium-to-Small Sized Pharmaceutical Players (to March 2005)	26
Table 1.7	Members of the Organisation of Pharmaceutical Producers of India	28
Table 2.1	List of Brand Names for Cephalexin, the Manufacturers and Price Comparisons	36
Table 2.2	Sales Distributions (%) of Selected Indian Drug Manufacturers by Region, 2006	41
Table 2.3	Ranbaxy Cases and Outcomes with Pfizer in Europe, 2005-2007	45
Table 2.4	Selected Indian Drug Company Acquisitions in North America	48
Table 2.5	Selected Indian Drug Company Acquisitions in Western Europe	49
Table 2.6	Selected Indian Drug Company Acquisitions in Eastern Europe	49
Table 3.1	Indian Trade Balance, 2000-2007 (US\$m)	54
Table 3.2	Comparison of Indian Data Exclusivity Proposals to Actual Practice in the West	58
Table 3.3	History of the Indian Patent System	61
Table 4.1	Analysis of Pharmaceutical Sales in India, Quarter ending March 2007	69
Table 4.2	Indices of Population and Economic Growth in India, 2004-2008	71
Table 4.3	Leading Indian Pharmaceutical Company Market Shares, 2004-2006	74
Table 4.4	Comparison of Indian Drug Sales by Value (US\$m) with Key International Territories (2005-2006) and Population Statistics	77
Table 5.1	Annual Sales Figures (Rs and US\$) for [Company], 2002-2007	87
Table 5.2	Annual Sales Figures (Rs and US\$) for [Company], 2002-2007	90
Table 5.3	Annual Sales Figures (Rs and US\$) for [Company], 2002-2007	92
Table 5.4	Annual Sales Figures (Rs and US\$) for [Company], 2002-2007	94
Table 5.5	Major [Company] Brands and Sales (Rs and US\$ million)	95
Table 5.6	Annual Sales Figures (Rs and US\$) for [Company], 2002-2007	97
Table 5.7	Annual Sales Figures (Rs and US\$) for [Company], 2002-2007	100
Table 5.8	[Company] Major Domestic Brands and Sales (Rps million), 2006-2007	100
Table 5.9	Annual Sales Figures (Rs and US\$) for [Company], 2002-2007	102
Table 5.10	Annual Sales Figures (Rs and US\$) for [Company], 2002-2007	104
Table 5.11	Annual Sales Figures (Rs and US\$) for [Company], 2002-2006	106
Table 5.12	Annual Sales Figures (Rs and US\$) for [Company], 2002-2007	109

Table 6.1	SWOT Analysis for the Indian Pharmaceutical Industry	113
Table 6.3	International Acquisition Targets by Indian Pharmaceutical Manufacturers, 2006-2007	117
Table 6.2	Patent Expiries of Leading Branded Drugs, 2007-2011	114
Table 6.4	Indian Pharmaceutical Research and Development Expenditure, 2000-2006	120
Table 7.1	Promising Drug Candidates in Development from Indian Pharmaceutical Companies	130
Table 7.2	Indian Drug Company Revenues from the US Market (1998, 2003, and 2008)	133
Table 7.3	Indian Companies: Current and Potential Turnovers, 2006 & 2012 (US\$m)	138

### **List of Figures**

Figure 2.1	Drug Master Files Submitted by Indian Companies, 1996-2005	38
Figure 2.2	United States Food and Drug Administration Approved Manufacturing Sites, 2006	41
Figure 2.3	Indian Abbreviated New Drug Applications (ANDAs) Approved by the United States Food and Drug Administration, 2001-2004	43
Figure 4.1	Indian Pharmaceutical Company Market Shares, 2004-2006	74
Figure 4.2	Value and Volume Growth Rates of the Indian Pharmaceutical Industry, 1993-2006	78

[www.SpectraIntelligence.com](http://www.SpectraIntelligence.com)

[www.ArrowheadPublishers.com](http://www.ArrowheadPublishers.com)